Form 8-K - Current report - Item 2.02 Item 9.01

Aethlon Medical Inc

Analyst Summary:

Aethlon Medical has reported financial results for its Q3 FY2022, including a cash balance of $17.5 million. The company is continuing to develop its Hemopurifier® therapeutic blood filtration system and recently contracted with NAMSA to direct their planned oncology study for solid tumors failing anti-PD-1 antibodies. The company also hired a new Chief Scientific Officer, Dr. Lee Arnold, who has led product development at five previous companies. Aethlon has ongoing preclinical studies to expand the potential utility of the Hemopurifier, including an mPox experiment and a study of Post-acute Sequelae of COVID-19 infection. The company raised approximately $8.9 million in net proceeds under its ATM agreement with H.C. Wainwright & Co. during the nine months ended December 31, 2022.

Announcement: AEMD 8-K Special Filing